Genomic accesssment of patients with HR+/HER2- metastatic breast cancer treated with palbociclib (PROMISE study)
RNA-seq (gene expression) · human · 39 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 39 samples: 22 × PRMS_R1 vs 10 × PRMS_R2 vs 3 × PRMS_F1 vs 3 × PRMS_A1Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE317345_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1406769. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 38 samples.
How we read this: 4 replicated groups read from 39 sample titles; they account for 38 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9470235 PRMS_R1_01 PRMS_R1
- GSM9470236 PRMS_F1_15 PRMS_F1
- GSM9470237 PRMS_F1_16 PRMS_F1
- GSM9470238 PRMS_A1_17 PRMS_A1
- GSM9470239 PRMS_A1_18 PRMS_A1
- GSM9470240 PRMS_R1_19 PRMS_R1
- GSM9470241 PRMS_F1_20 PRMS_F1
- GSM9470242 PRMS_R1_22 PRMS_R1
- GSM9470243 PRMS_R2_23 PRMS_R2
- GSM9470244 PRMS_R1_28 PRMS_R1
- GSM9470245 PRMS_R2_02 PRMS_R2
- GSM9470246 PRMS_R1_14 PRMS_R1
- GSM9470247 PRMS_R2_26 PRMS_R2
- GSM9470248 PRMS_R1_35 PRMS_R1
- GSM9470249 PRMS_R1_36 PRMS_R1
- GSM9470250 PRMS_R2_60 PRMS_R2
- GSM9470251 PRMS_R1_06 PRMS_R1
- GSM9470252 PRMS_R1_09 PRMS_R1
- GSM9470253 PRMS_R1_10 PRMS_R1
- GSM9470254 PRMS_R1_11 PRMS_R1
- GSM9470255 PRMS_R2_37 PRMS_R2
- GSM9470256 PRMS_R1_25 PRMS_R1
- GSM9470257 PRMS_R1_30 PRMS_R1
- GSM9470258 PRMS_R1_38 PRMS_R1
- GSM9470259 PRMS_R1_43 PRMS_R1
- GSM9470260 PRMS_R1_44 PRMS_R1
- GSM9470261 PRMS_R1_51 PRMS_R1
- GSM9470262 PRMS_R1_50 PRMS_R1
- GSM9470263 PRMS_R2_53 PRMS_R2
- GSM9470264 PRMS_R2_63 PRMS_R2
- GSM9470265 PRMS_R1_65 PRMS_R1
- GSM9470266 PRMS_R1_54 PRMS_R1
- GSM9470267 PRMS_A1_46 PRMS_A1
- GSM9470268 PRMS_R1_31 PRMS_R1
- GSM9470269 PRMS_R2_57 PRMS_R2
- GSM9470270 PRMS_R1_58 PRMS_R1
- GSM9470271 PRMS_R2_66 PRMS_R2
- GSM9470272 PRMS_R2_42 PRMS_R2
- GSM9470273 PRMS_F2_56
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing · shares breast
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing · shares breast
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing · shares breast
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing · shares breast
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE317681 Genomic accesssment of patients with HR+/HER2- metastatic breast cancer treated with palbociclib (PROMISE_study) 49 samples shares promise, her2, accesssment, palbociclib, metastatic, treated, breast
- GSE317628 Genomic accesssment of patients with HR+/HER2- metastatic breast cancer treated with palbociclib (PROMISE study) paired 10 samples shares promise, her2, accesssment, palbociclib, metastatic, treated, breast
- GSE270021 Targeting ferroptosis resistance re-sensitizes metastatic HR+ HER2- breast cancer to palbociclib-hormone therapy 21 samples shares her2, palbociclib, metastatic, breast
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.